Back to search

Article

Efficacy of Bivalent CEACAM6/4-1BBL Genetic Vaccine Combined with Anti-PD1 Antibody in HCT116 Xenograft Mice

2021-08-04

Abstract excerpt

<h4>Background: </h4> Colorectal cancer (CRC) is the second leading cause of cancer death worldwide. Anti-PD1/PD-L1 drugs are feasible treatment for CRC, and genetic vaccine is a promising immunotherapy for cancers. However, anti-tumor efficacy of genetic vaccines including CEACAM6/4-1BBL genes combined with immunocheckpoint inhibitors on CRC has not been reported. We used human colon cancer cell line (HCT116) to...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8e3c1378-3aac-5a90-a967-833d21a65d61
DOI
10.21203/rs.3.rs-618292/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Efficacy of Bivalent CEACAM6/4-1BBL Genetic Vaccine Combined with Anti-PD1 Antibody in HCT116 Xenograft MiceDOI 10.21203/rs.3.rs-618292/v1
Select a neighboring publication to make it the new centre.